BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 24339346)

  • 21. The B-cell specific transcription factor, Oct-2, promotes Epstein-Barr virus latency by inhibiting the viral immediate-early protein, BZLF1.
    Robinson AR; Kwek SS; Kenney SC
    PLoS Pathog; 2012 Feb; 8(2):e1002516. PubMed ID: 22346751
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contribution of myocyte enhancer factor 2 family transcription factors to BZLF1 expression in Epstein-Barr virus reactivation from latency.
    Murata T; Narita Y; Sugimoto A; Kawashima D; Kanda T; Tsurumi T
    J Virol; 2013 Sep; 87(18):10148-62. PubMed ID: 23843637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of a novel element involved in regulation of the lytic switch BZLF1 gene promoter of Epstein-Barr virus.
    Kraus RJ; Mirocha SJ; Stephany HM; Puchalski JR; Mertz JE
    J Virol; 2001 Jan; 75(2):867-77. PubMed ID: 11134300
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PARP1 restricts Epstein Barr Virus lytic reactivation by binding the BZLF1 promoter.
    Lupey-Green LN; Moquin SA; Martin KA; McDevitt SM; Hulse M; Caruso LB; Pomerantz RT; Miranda JL; Tempera I
    Virology; 2017 Jul; 507():220-230. PubMed ID: 28456021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epstein-Barr virus BZLF1 gene, a switch from latency to lytic infection, is expressed as an immediate-early gene after primary infection of B lymphocytes.
    Wen W; Iwakiri D; Yamamoto K; Maruo S; Kanda T; Takada K
    J Virol; 2007 Jan; 81(2):1037-42. PubMed ID: 17079287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BZLF1 governs CpG-methylated chromatin of Epstein-Barr Virus reversing epigenetic repression.
    Woellmer A; Arteaga-Salas JM; Hammerschmidt W
    PLoS Pathog; 2012 Sep; 8(9):e1002902. PubMed ID: 22969425
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histone acetylation and reactivation of Epstein-Barr virus from latency.
    Jenkins PJ; Binné UK; Farrell PJ
    J Virol; 2000 Jan; 74(2):710-20. PubMed ID: 10623733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histone Loaders CAF1 and HIRA Restrict Epstein-Barr Virus B-Cell Lytic Reactivation.
    Zhang Y; Jiang C; Trudeau SJ; Narita Y; Zhao B; Teng M; Guo R; Gewurz BE
    mBio; 2020 Oct; 11(5):. PubMed ID: 33109754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Luteolin inhibits Epstein-Barr virus lytic reactivation by repressing the promoter activities of immediate-early genes.
    Wu CC; Fang CY; Hsu HY; Chen YJ; Chou SP; Huang SY; Cheng YJ; Lin SF; Chang Y; Tsai CH; Chen JY
    Antiviral Res; 2016 Aug; 132():99-110. PubMed ID: 27185626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TORC2, a coactivator of cAMP-response element-binding protein, promotes Epstein-Barr virus reactivation from latency through interaction with viral BZLF1 protein.
    Murata T; Sato Y; Nakayama S; Kudoh A; Iwahori S; Isomura H; Tajima M; Hishiki T; Ohshima T; Hijikata M; Shimotohno K; Tsurumi T
    J Biol Chem; 2009 Mar; 284(12):8033-41. PubMed ID: 19164291
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulation of the BZLF1 promoter of Epstein-Barr virus by second messengers in anti-immunoglobulin-treated B cells.
    Daibata M; Speck SH; Mulder C; Sairenji T
    Virology; 1994 Feb; 198(2):446-54. PubMed ID: 8291228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of Epstein-Barr virus reactivation in nasopharyngeal carcinoma cells by dietary sulforaphane.
    Wu CC; Chuang HY; Lin CY; Chen YJ; Tsai WH; Fang CY; Huang SY; Chuang FY; Lin SF; Chang Y; Chen JY
    Mol Carcinog; 2013 Dec; 52(12):946-58. PubMed ID: 22641235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epstein-Barr Virus BZLF1-Mediated Downregulation of Proinflammatory Factors Is Essential for Optimal Lytic Viral Replication.
    Li Y; Long X; Huang L; Yang M; Yuan Y; Wang Y; Delecluse HJ; Kuang E
    J Virol; 2016 Jan; 90(2):887-903. PubMed ID: 26537683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. B cells infected with Type 2 Epstein-Barr virus (EBV) have increased NFATc1/NFATc2 activity and enhanced lytic gene expression in comparison to Type 1 EBV infection.
    Romero-Masters JC; Huebner SM; Ohashi M; Bristol JA; Benner BE; Barlow EA; Turk GL; Nelson SE; Baiu DC; Van Sciver N; Ranheim EA; Gumperz J; Sherer NM; Farrell PJ; Johannsen EC; Kenney SC
    PLoS Pathog; 2020 Feb; 16(2):e1008365. PubMed ID: 32059024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ERK/c-Jun Recruits Tet1 to Induce Zta Expression and Epstein-Barr Virus Reactivation through DNA Demethylation.
    Zhang W; Han D; Wan P; Pan P; Cao Y; Liu Y; Wu K; Wu J
    Sci Rep; 2016 Oct; 6():34543. PubMed ID: 27708396
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epstein-Barr Virus Lytic Cycle Reactivation.
    McKenzie J; El-Guindy A
    Curr Top Microbiol Immunol; 2015; 391():237-61. PubMed ID: 26428377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. hTERT inhibition triggers Epstein-Barr virus lytic cycle and apoptosis in immortalized and transformed B cells: a basis for new therapies.
    Giunco S; Dolcetti R; Keppel S; Celeghin A; Indraccolo S; Dal Col J; Mastorci K; De Rossi A
    Clin Cancer Res; 2013 Apr; 19(8):2036-47. PubMed ID: 23444223
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EBV-immortalized isogenic human B-cell clones exhibit differences in DNA-protein complex formation on the BZLF1 and BRLF1 promoter regions among latent, lytic and TPA-activated cell lines.
    Cen H; McKnight JL
    Virus Res; 1994 Jan; 31(1):89-107. PubMed ID: 8165871
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nascent Transcriptomics Reveal Cellular Prolytic Factors Upregulated Upstream of the Latent-to-Lytic Switch Protein of Epstein-Barr Virus.
    Frey TR; Brathwaite J; Li X; Burgula S; Akinyemi IA; Agarwal S; Burton EM; Ljungman M; McIntosh MT; Bhaduri-McIntosh S
    J Virol; 2020 Mar; 94(7):. PubMed ID: 31941784
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A molecular link between malaria and Epstein-Barr virus reactivation.
    ChĂȘne A; Donati D; Guerreiro-Cacais AO; Levitsky V; Chen Q; Falk KI; Orem J; Kironde F; Wahlgren M; Bejarano MT
    PLoS Pathog; 2007 Jun; 3(6):e80. PubMed ID: 17559303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.